Case Study: Costa Michalos's Journey with Cancer
Condition - Post Chemotherapy:
Stage 4 Lymphoma, Multiple Myeloma, Bone Cancer, Severe post-chemo myopathy, Multiple, spinal disk disintegration.
Intervention:
- Costa started KineDek sessions on 28 December 2022 after intense chemotherapy.
- Initial sessions were light since Costa had previously crushed 2 vertebrae when picking up a light load. Increased loading systematically where initially a downward weight such as bicep curl 3kg would induce intense spinal pain, while by 7 December 2023 he could comfortably do deadlifts at 25kg without any strain on his muscles of bones.
- By 22 April 2023 Costa's blood was in normal range. He had not taken any blood transfusion or other blood work since his religious beliefs prohibits it.
- Costa did not succumb to any infections in this period, although his haematologist (appointment on 16 October 2023) did indicate that his body had successfully fought off a virulent respiratory strain that was experienced at that time. It was the view of the haematologist that any infection could be deadly and was particularly vigilant in this regard.
- After not doing sessions between 18 December 2023 and 3 January 2024, Costa was experiencing low mood and energy, and general weakness, which was improved by after the session on January 2024.
Outcome:
Condition - Cancer Relapse:
On May 2nd, it came to light that Costa's cancer had resurfaced aggressively. His physician indicated that it was incurable, and based on his Lactate Dehydrogenase (LDH) levels, which is an indicator of the degree of cellular decay, he likely only had a few weeks, if not days, to live, and that chemotherapy was not advised.
Intervention:
- On May 2nd, it came to light that Costa's cancer had resurfaced aggressively. His physician indicated that it was incurable, and based on his Lactate Dehydrogenase (LDH) levels, which is an indicator of the degree of cellular decay, he likely only had a few weeks, if not days, to live, and that chemotherapy was not advised.
- Before his KineDek session following the diagnosis, he endured intense pain, especially in his kidney area, along with feelings of fatigue and general discomfort. Strong pain and anti-inflammatory medicines were not advised because of kidney weakness. The session managed to alleviate his pain to a mild tolerable level. It also appeared to invigorate him, as evident by a improvement in his complexion and increased energy levels for a few days thereafter. However, the pain and discomfort resurfaced after four days, prompting two weekly sessions instead of one.
- After his session on May 27, 2024, his pain abated and had not resurfaced since.
- Once weekly sessions was resumed thereafter.
- After tests on June 4, 2024, it was found that Costa's LDH levels had not significantly increased, indicating that the cancer had not caused the amount of cellular damage as was expected. Aggressive chemotherapy was introduced on the same day.
- Costa experienced the typical side effects of chemotherapy, such as nausea, weakness, severe neuropathy in his jaw and feet, and a uncomfortable sensitivity to taste.
Outcome:
After his KineDek session on June 10, 2024, he experienced alleviation of many of the side effects after the session, including temporary relaxation, improved mood, and improved skin tone. There was also a noticeable and prolonged abatement of neuropathy and sensitivity to taste.
By his 2nd KineDek session after chemotherapy, he performed robustly with near normal strength and functionality.
Costa had his final chemotherapy session on September 17, 2024, and appeared in good physical condition, with no neuropathy and minimal other symptoms.
Notes:
KineDek sessions prior to his subsequent cancer diagnosis were initially focused on muscle and strength gains. They were light at first due to his limited strength and bone weakness. However, these sessions were progressively increased to the point where he showed significant strength and functionality. These sets were usually taken to an extreme lactate burn or exhaustion.
It's imperative to acknowledge that while KineDek doesn't offer a cure for cancer, it does play a crucial role in preserving muscle function and lowering levels of inflammation, thereby complementing cancer treatment and aiding in recovery, even in advanced stages of the disease. This is particularly significant in mitigating the adverse effects of both cancer and its treatments..
Post-cancer diagnosis sessions were light and focused on longer sets, and were not taken to exhaustion. They usually induce a calm, floaty feeling described as a high, and usually induce drowsiness and sleepiness. This is indicative of an endocannabinoid response being achieved.
It's imperative to acknowledge that while KineDek doesn't offer a cure for cancer, it does play a crucial role in preserving muscle function and lowering levels of inflammation, thereby complementing cancer treatment and aiding in recovery, even in advanced stages of the disease. This is particularly significant in mitigating the adverse effects of both cancer and its treatments.
Audio Testimony
[From WhatsApp voice messages received]
Disclaimer: The above has been feedback from the personal experiences of an individual who have used the KineDek. These accounts are individual to each person and are not to be taken as a guarantee that others will experience the same outcomes. The KineDek is not presented as a cure for any condition. Rather, it serves as an enabler for exercise, particularly for those who may otherwise find traditional forms of exercise challenging or painful. Through its AI-enabled Compensating Resistance Technology (AI-CRT), the KineDek allows individuals to engage in physical activity without perceived pain, strain, or subsequent inflammation. Consequently, users can enjoy the well-documented benefits of "Exercise as Medicine." If you have a serious medical condition, always consult with a healthcare professional before starting any new exercise regimen.